Targeted β <sup>−</sup> -Particle Plus Conversion and Auger-Electron Therapy with <sup>161</sup> Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study
Year: 2025
Type: article
Language: en
Topic: Neuroendocrine Tumor Research Advances
Authors and affiliations:
raw_author_name: Julia G. Fricke
raw_affiliation_strings: Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
raw_author_name: Frida Westerbergh
raw_affiliation_strings: Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
raw_author_name: Lisa McDougall
raw_affiliation_strings: Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
raw_author_name: Chiara Favaretto
raw_affiliation_strings: Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland
Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
raw_author_name: Emanuel Christ
raw_affiliation_strings: Division of Endocrinology, University Hospital Basel, Basel, Switzerland
ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland
raw_author_name: Guillaume P. Nicolas
raw_affiliation_strings: Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland
raw_author_name: Susanne Geistlich
raw_affiliation_strings: Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland
raw_author_name: David E. Schmid
raw_affiliation_strings: Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland
raw_author_name: Francesca Borgna
raw_affiliation_strings: Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland
raw_author_name: Melpomeni Fani
raw_affiliation_strings: Division of Radiopharmaceutical Chemistry, University Hospital Basel, Basel, Switzerland
raw_author_name: Peter Bernhardt
raw_affiliation_strings: Department of Medical Physics and Biomedical Engineering, Sahlgrenska University Hospital, Gothenburg, Sweden
Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
raw_author_name: Nicholas P. van der Meulen
raw_affiliation_strings: Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland
Laboratory of Radiochemistry, PSI Center for Nuclear Engineering and Sciences, Villigen-PSI, Switzerland; and
Laboratory of Radiochemistry, PSI Center for Nuclear Engineering and Sciences, Villigen-PSI, Switzerland
raw_author_name: Cristina Müller
raw_affiliation_strings: Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland
Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
raw_author_name: Roger Schibli
raw_affiliation_strings: Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, Villigen-PSI, Switzerland
Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
raw_author_name: Damian Wild
raw_affiliation_strings: Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland; damian.wild@usb.ch
ENETS Center of Excellence for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Basel, Switzerland
Division of Nuclear Medicine, University Hospital Basel, Basel, Switzerland